Development, manufacture and supply of its Hailie digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.
|Head Office||Auckland New Zealand|
|Registry||Computershare Investor Services Pty Ltd|
|GICS Industry||Health Care Equipment & Services|
|Sub Industry||Health Care Technology|
|Market Cap||$15 m|
|Shares on Issue||4,996 b|
|52 Week H/L|
Directors and Management
Dr William (Bill) Lawrence Hunter
Non-Executive Director 17/12/2015
Dr Hunter has experience in commercialising medical device technologies. He co-founded Angiotech Pharmaceuticals in 1992 and assumed the position of CEO in 1997 when Angiotech was a venture-stage, private, pre-clinical company with less than 50 employees. He led Angiotech through its IPO and listing on the Toronto Stock Exchange and NASDAQ. Dr Hunter has over 200 patents and patent applications to his name and products in which he was an inventor or co-inventor, including the TAXUS Drug-Eluting Coronary Stent, the Zilver PTX Peripheral Drug-Eluting Stent, the Quill barbed wound closure device and the 5-FU Anti-Infective Catheter. He is currently President and CEO of Canary Medical Inc. and formerly Correvio Pharma Corp (NASDAQ: CORV). Dr Hunter is also a Director of Rex Bionics and an Industry Expert Advisor for BioScience Managers. He has previously served as a director of Epirus Biopharmaceuticals (NASDAQ: EPRS) and Union Medtech.
Mr Bruce Fielding McHarrie
Non-Executive Director 20/07/2015
Mr McHarrie is currently an independent director and consultant with over 20 years' experience in the health and life sciences sectors. He was formerly with Telethon Kids Institute in Perth, Western Australia, for 15 years, where his roles included Chief Financial Officer, Director of Operations and Director of Strategic Projects. Prior to joining Telethon Kids, Mr McHarrie was a Senior Manager at Deloitte in London before moving to Rothschild Asset Management as Assistant Director of the Bioscience Unit. Outside his role at Adherium, he is currently an advisor to BioScience Managers, a director at AusCann (Australasian Medical Cannabis) and an independent consultant. As noted, as an advisor to BioScience Managers, Mr McHarrie has an association with shareholder of the Company. He is Chair of Risk Committee.
BCom, FCA, GAICD Chartered Accountant Male
Mr Jeremy Curnock-Cook
Non-Executive Director 17/04/2015
Mr Curnock-Cook was formerly head of the life science private equity team at Rothschild Asset Management in the UK and an active investor in the Australian life science sector. At Rothschild, Mr Curnock-Cook was responsible for the launch of the biotechnology fund for the Australian market. Over his 40-year career, Mr Curnock-Cook has specialised in creating value in emerging biotech enterprises, through participation with management. He has served on over 40 boards in various roles, including chair of private and public biotechnology companies listed on NASDAQ, LSE, TSX and ASX. He is currently Managing Director of BioScience Managers (manager of a major shareholder in Adherium), Chairperson of Avena Therapeutics and AmpliPhi Biosciences and sits on the board of Avita Medical, Rex Bionics Pty and Sea Dragon Ltd. Mr Curnock-Cook was previously a director of Bioxyne Limited and Phylogica Limited.
BA (Hons), MA (Natural Sciences) Male
Mr Matthew Patrick McNamara
Non-Executive Director 18/10/2019
Mr McNamara is currently the Chief Investment Officer and director of Horizon 3 Biotech Pty Ltd. Mr McNamara has over 25 years' experience in the Healthcare & Medical Sciences sector. After initially being a Molecular Biology Research Assistant, he spent 11 years in sales & marketing and general management with Merck & Co. and Johnson and Johnson Medical Pty Ltd respectively. He was CEO of a Life Sciences Venture Capital Fund, SciCapital Pty Ltd and from 2005 - 2019 was CIO of BioScience Managers' healthcare funds. He is Member of Risk Committee.
BSc(Hons -Molecular Biology),MBA Male
Mr James Ward-Lilley
Non Executive Chairman and Director 14/04/2020
Mr Ward-Lilley had 28 years global pharmaceutical career at AstraZeneca before becoming Chief Executive Officer of Vectura Group PLC in September 2015. At Vectura he was responsible for leading the business through a period including the merger with Skye pharma. James stepped down in June 2019. At AstraZeneca James had a number of senior roles. He went on to become Regional Vice President for Central Eastern Europe and the Middle East and led AstraZeneca's investor relations team during the transition of Chair, CEO and strategy as Leif Johansson and Pascal Soriot joined the business. Mr Ward-Lilley's last role at AstraZeneca was to lead the Respiratory, Inflammation & Autoimmunity franchise with responsibility for the revitalisation of one of AstraZeneca's three therapeutic areas including the acquisitions of Almirall's respiratory business and Pearl Therapeutics. He was responsible for leading AstraZeneca's corporate device strategy in 2014/15 and was sponsor for AstraZeneca's initial investment in Adherium at the time of the IPO in 2015. Mr Ward-Lilley is CCO for UK based Aerogen Group and a director for its subsidiary Aerogen Pharma Ltd.
Mr George Baran
Non-Executive Director 13/05/2021
Mr Baran has over 35 years of experience in the medical device industry and serves as Executive Chair of the Trudell Medical Limited Board of Directors as well as being a significant shareholder. In addition to his role at Trudell, George is an investor in and Director of several medical device and e-health / connected care companies including Sensory Technologies, Mozzaz Corporation, and Sky Medical Technology Inc. He was also a lead investor and a former Director of Vanrx Phamasystems, which was recently acquired by Cytiva Life Sciences. George has been responsible for the marketing of new drug delivery technologies to medical opinion leaders and major pharmaceutical companies. This has included collaboration with business and clinical partners in the design and co-ordination of clinical studies. He has also been granted several US and international patents for medical devices for drug delivery and minimally invasive surgery. He currently serves on the Advisory Board of the Lawrence National Centre for Policy and Management at Richard Ivey School of Business, Western University, London (ON).
Top 20 Shareholders
|1.||Phillip Asset Management Limited (Bioscience Trans Fund 1 A/C)||500,000,000||23.48|
|2.||Trudell Medical Ltd||422,697,512||19.85|
|3.||J P Morgan Nominees Australia Pty Limited||246,069,991||11.56|
|4.||Cs Third Nominees Pty Limited (Hsbc Cust Nom Au Ltd 13 A/C)||222,266,463||10.44|
|5.||HSBC Custody Nominees (Australia) Limited||220,770,692||10.37|
|6.||K One W One Ltd||80,503,018||3.78|
|7.||One Funds Management Limited (Asia Pac Health Fund Ii A/C)||48,808,957||2.29|
|8.||Citicorp Nominees Pty Limited||39,820,698||1.87|
|9.||Summatix Pty Ltd||35,496,341||1.67|
|10.||National Nominees Limited||30,000,000||1.41|
|11.||BNP Paribas Noms (Nz) Ltd (Drp)||28,616,873||1.34|
|12.||Planet Innovation Pty Ltd||26,666,667||1.25|
|13.||Jmid Pty Ltd (Jam Superfund A/C)||25,550,000||1.20|
|15.||HSBC Custody Nominees (Australia) Limited A/C 2||11,204,336||0.53|
|16.||Adherium Esp Trustee Limited||10,303,149||0.48|
|17.||Calcium Investments Limited||7,112,779||0.33|
|18.||Mr Carlsen Wilson Henry Marks & Mrs Edwina Mary Marks||6,250,000||0.29|
|19.||Mr Garth Campbell Sutherland||5,174,885||0.24|
|20.||Cs Fourth Nominees Pty Limited (Hsbc Cust Nom Au Ltd 11 A/C)||4,703,232||0.22|
|07/05/2021||William (Bill) Hunter||1,083,705||$25,000||Issued||Director remuneration.|
|07/05/2021||Bruce McHarrie||1,083,705||$25,000||Issued||Director remuneration.|
|07/05/2021||Jeremy Curnock-Cook||1,083,705||$25,000||Issued||Director remuneration.|
|07/05/2021||Matthew McNamara||1,083,705||$25,000||Issued||Director remuneration.|
|07/05/2021||James Ward-Lilley||2,167,412||$50,000||Issued||Director remuneration.|
|14/04/2021||Mike Motion||10,000,000||$170,000||Expiry||Options expired. As per announcement on 19/05/2021.|